This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pristiq

Pfizer Inc.

Drug Names(s): DVS-233, desvenlafaxine succinate, Ellefore

Description: Pristiq is a new chemical entity that is a dual serotonin and norepinephrine reuptake inhibitor (SNRI). It is the major metabolite of venlafaxine (Effexor).

Deal Structure: Pristiq was originally developed by Wyeth.

In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.

Impax Laboratories announced that beginning July 1, 2009, Impax Pharmaceuticals, the Company's specialty brand products division will co-promote Wyeth's Pristiq. Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.

In April 2010, Impax announced that it amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of Pfizer. Impax will now detail Lyrica CV for use as adjunctive therapy for...See full deal structure in Biomedtracker


Pristiq News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug